Roivant Sciences(ROIV) - 2023 Q1 - Earnings Call Transcript

Yes. Thanks, Brian. And maybe IÂ'll take one second to that question and then also hand it over to Mayukh, to see if heÂ's got further comments. Look, I think in terms of the confidence in SLA, and I think you heard Mayukh said, on the one hand, I think thereÂ's a strong biological rationale that hitting both TYK2 and JAK1 should provide a meaningful benefit. Mayukh Sukhatme And maybe just one more follow-up on Immunovant 1402 data coming up next next month. Just to prep us for the top line coming up. Can y ...